Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Pain Management & Beyond: Paul Howe from Protega Pharmaceuticals in a Stimulating Conversation with PharmaShots 

Shots: Abuse-deterrent products are prescription medications, primarily opioids and certain stimulants, designed to resist common methods of misuse, such as crushing, snorting, or injecting Protega Pharmaceuticals’ RoxyBond is the first and only FDA-approved, immediate-release abuse-deterrent opioid indicated for managing severe pain when alternative treatments are inadequate PharmaShots is pleased to feature Paul Howe, Chief Operations…
September 17, 2025

Read more

Spotlight Interview_Philippe Barillon
SPOTLIGHT

Reuters Pharma 2025: Pre-Conference Talks Featuring Philippe Barillon

Philippe Barillon joins PharmaShots Managing Editor Himanshu Sehgal for an enlightening dialogue exchange in a Pre-Conference Talk.Philippe will be joining the upcoming Reuters Events Pharma 2025 as a panelist for the topic “Bridging gaps: Leverage data, tech and RWE for enhanced healthcare access and market growth”.Philippe highlights the potential applications of RWEs using…
April 7, 2025

Read more

ThoughtSpot_David Fox
THOUGHTSPOT

Innovative Orthodontic Technologies Transform Patient Care Experience

The orthodontic industry is witnessing a significant transformation due to technological advancements. These innovations are not only enhancing the precision of treatments but are also elevating patient experiences. As technology continues to evolve, the way orthodontic care is delivered is undergoing a remarkable change.In recent years, the field of orthodontics has experienced a profound…
March 27, 2025

Read more

Know Your Investor- Surveyor Capital (December’24 Edition) 
INSIGHTS+

Know Your Investor: Surveyor Capital (December’24 Edition) 

Shots:  A longstanding equities business within Citadel, Surveyor Capital invests in the consumer, financials, healthcare, industrials, and Technology, Media & Telecom sectors In 2023, Surveyor participated in four funding rounds, investing approximately $2.35B and adding 17 companies to its portfolio For a curated report on a specific investor or venture capital firm, reach out to…
December 5, 2024

Read more

VIEWPOINTS_Raviv Pryluk_2024
VIEWPOINTS

Technology Infusion: Raviv Pryluk Sheds Light on PhaseV’s Recent Collaboration with 9xchange Biopharma Marketplace

Shots:  Raviv Pryluk, CEO and Co-Founder of PhaseV, in a stimulating conversation with PharmaShots, sheds light on the company’s recent partnership with 9xchange Biopharma   The partnership aims to bring Phase V’s proprietary machine learning (ML) technology to ecosystem members, enabling them, to retrospectively analyze and optimally design and execute advanced clinical studies  Raviv highlights the…
April 23, 2024

Read more

ThoughtSpot_Fatima Batool8
THOUGHTSPOT

How Innovations in Technology Can Mitigate Healthcare Disparities

Technological innovations have already had a transformative effect on healthcare education, with ABSN programs and accelerated BSN online programs now readily available to those studying nursing. But in the realm where technology converges with universal healthcare, this article navigates through cutting-edge innovations such as telehealth, remote monitoring, mobile health apps, virtual reality (VR), and augmented reality (AR). …
March 11, 2024

Read more

ThoughtSpot_Jessica Fisher
THOUGHTSPOT

Technology’s Impact on Training Future Healthcare Personnel

The integration of cutting-edge technological tools and methodologies has revolutionized the way healthcare education is delivered, offering both educators and students unparalleled opportunities for growth and learning. This article delves into the profound impact of technology on the training of future healthcare professionals, highlighting the transformative potential it holds for preparing a new generation of…
February 21, 2024

Read more

Load more